Compare NextEra Energy, Inc. (NEE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Sanofi SA — how do they compare? NextEra Energy, Inc. trades at $77.46 (market cap $160.75B), while Sanofi SA trades at $40.36 (market cap $96.81B). The key difference: NextEra Energy, Inc. is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold NextEra Energy, Inc. for 83 Days and Sanofi SA for 94 Days on average.
| NEE | SNY | |
|---|---|---|
Market Cap | $160.75B | $96.81B |
Volume | 10,598,021 | 2,081,815 |
Sector | Utilities | Health |
52-Week High | $97.88 | $52.34 |
52-Week Low | $75.49 | $39.51 |
Typical Hold Time | 83 Days | 94 Days |
Enterprise Value | $268.08B | $116.20B |
Dividend Yield | 3.23% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $77.37, down 0.65% with a bearish technical signal. The stock shows strong fundamentals with 32.4% net income margin and 17.23% ROE, though recent earnings were mixed with a Q4 miss but Q1-Q2 beats. Analyst consensus remains bullish with 66.7% buy ratings and $96 price target. Recent news highlights growth opportunities including a $22.3 billion energy infrastructure partnership and 18 GW gas development prospects.
NEE presents a compelling long-term investment case with robust profitability and analyst support, though near-term technical weakness and rising debt levels warrant caution. The company's clean energy transition strategy and infrastructure projects provide growth catalysts, but interest rate sensitivity and execution risks on large projects represent key challenges for investors.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
